VENCLYXTO

Phase 2Small molecule

FFirst Affiliated Hospital of Zhejiang University

VENCLYXTO is one of 4 small molecule programs targeting Prolonged. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ProlongedRecruiting

ProlongedPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Prolonged

#DrugCompanyPhaseTrials

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 2

VENCLYXTO

FFirst Affiliated Hospital of Zhejiang University

Phase 2

1 3

Xatral XL

IInternational Bio service

Phase 1

1 4

Alfuzosin Hydrochloride

UUniversity of Minnesota

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Prolonged

NCT06046313

Clinical

Trials by Indication[1]

Prolonged1 trial

Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS

Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT06046313·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for VENCLYXTO. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VENCLYXTO compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VENCLYXTO. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — First Affiliated Hospital of Zhejiang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFirst Affiliated Hospital of Zhejiang University

VENCLYXTO

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Prolonged1 trial

References

Drug Info

Quick Facts

Related News